Dark Forest Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Dark Forest Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$49	–	1177
2022 Q4	$49	Sell	1 -168	-99%	-$17.5K	﹤0.01%	1088
2022 Q3	$16K	Buy	169 +135	+397%	+$15.2K	﹤0.01%	650
2022 Q2	$7K	Buy	+34	New	+$5.55K	﹤0.01%	570
2022 Q1	–	Sell	-12	Closed	-$5K	–	1271
2021 Q4	$5K	Sell	12 -11	-48%	-$4.63K	﹤0.01%	1138
2021 Q3	$10K	Sell	23 -278	-92%	-$99.6K	﹤0.01%	980
2021 Q2	$117K	Buy	+301	New	+$107K	0.05%	287

Other funds holding ATRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dark Forest Capital Management's ATRA Position: Q1 2023 in Review

Dark Forest Capital Management sold out of Atara Biotherapeutics (ATRA) in Q1 2023, closing a stake of 1 share — an estimated $49 sold.

Dark Forest Capital Management first reported a position in ATRA in Q2 2021 and held it in 6 quarters. The position peaked at $117K in Q2 2021. 125 funds tracked by Wall St. Rank hold ATRA as of Q1 2023.

Dark Forest Capital Management reported no remaining Atara Biotherapeutics position as of Q1 2023 after selling out during the quarter.
Dark Forest Capital Management sold 1 Atara Biotherapeutics share in Q1 2023, an estimated $49.
Dark Forest Capital Management first reported a position in Atara Biotherapeutics in Q2 2021 and held it in 6 quarters.
Dark Forest Capital Management's Atara Biotherapeutics position peaked at $117K in Q2 2021.
125 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2023.

Based on Dark Forest Capital Management's 13F filing for Q1 2023, filed 12 May 2023.